A continuación, se enumeran los ensayos clínicos actuales.
Filtra esta lista de estudios por sede, estatus, etc.
Rochester, Minn.
This clinical trial is studying long-term follow-up in patients who are or have participated in Children's Oncology Group studies. Developing a way to track patients enrolled in Children's Oncology Group studies will help doctors gather long-term follow-up information and may help the study of cancer in the future.
The purpose of this study is to determine how well cisplatin and combination chemotherapy works in treating children and young adults with hepatoblastoma or liver cancer after surgery. Drugs used in chemotherapy, such as cisplatin, doxorubicin, fluorouracil, vincristine sulfate, carboplatin, etoposide, irinotecan, sorafenib, gemcitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving combination chemotherapy after surgery may kill more tumor cells.
The purpose of this study is to evaluate how children and young adults perceive their midline sternotomy scars (in terms of appearance, associated symptoms, consciousness, satisfaction with appearance/symptoms, and impact on quality of life)?
The purpose of this study is to determine the time from intramuscular injection to the time of first fetal movement after a fetal surgery procedure.
Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.
The purpose of this study is to evaluate the probable benefit and safety of the LIPOSORBER® LA-15 System for the treatment of adult and pediatric patients with nephrotic syndrome associated with primary focal segmental glomerulosclerosis, when the standard treatment options, including corticosteroid and/or calcineurin inhibitors treatments, have been unsuccessful or not well tolerated, and the patient has a GFR ≥ 45 ml/min/1.73m2, or the patient is post renal transplantation. Treatment for FSGS is considered unsuccessful if the patient is unresponsive to standard therapy (e.g., at least 8 weeks of corticosteroids) and fails to achieve complete or partial remission. A standard treatment is considered not well tolerated if the patient experiences severe side effects without providing an acceptable level of clinical benefit.
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with CD22 positive B acute lymphoblastic leukemia that has come back or does not respond to treatment. Immunotoxins, such as inotuzumab ozogamicin, are antibodies linked to a toxic substance and may help find cancer cells that express CD22 and kill them without harming normal cells.
To determine the effectiveness of the ARTISAN Aphakia lens in the treatment of aphakia and to precisely define the associated risks and, if possible, identify particular groups of patients who may be at high risk of developing complications resulting from the surgical procedure of implanting an ARTISAN Aphakia lens.
The purpose of this study is to pilot test the ENHANCE intervention to evaluate methodology, feasibility based on caregiver input, and preliminary caregiver satisfaction. The primary outcomes will be feedback from parents, participant completion/atrition rates, the interventionist study log, and interventionist/caregiver/fidelity. Second, we aim to examine preliminary impact of the naturalistic intervention on child social communication and repetitive behavior in order to estimate clinically meaningful change for future research studies.
The purpose of this study is to develop a prospective status epilepticus registry among twelve tertiary care pediatric hospitals in the United States focused on standardizing status epilepticus outcome assessments.
This protocol is being designed to offer testicular tissue cryopreservation to male pediatric patients (0-17 years of age) with fertility threatening medical diagnoses or facing surgery, chemotherapy or radiation therapy that may cause loss of reproductive potential.
¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?